KAPA (Kairos Pharma) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 30, 2026)


KAPA Kairos Pharma Ltd KAPA
15 GF Score
Price $0.38
View Full Analysis

What is Kairos Pharma Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Kairos Pharma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

KAPA vs IMNN, HCWB, CURX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Kairos Pharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kairos Pharma Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kairos Pharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Kairos Pharma's Margin of Safety % (DCF Earnings Based) falls into.


KAPA
15GF Score
Kairos Pharma Ltd KAPA
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kairos Pharma Business Description

Address 2355 Westwood Boulevard, No. 139, Los Angeles, CA, USA, 90064
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
15GF Score

Get the complete analysis for KAPA

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.38
Price